


# UBS Equity Sust Health Transformation

## Performance **Review**

UBS (Lux) Equity Fund - Sustainable Health Transformation (USD) P-acc



### Performance (basis USD, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

### Performance in % (net of fees)<sup>1</sup>

in %	2019	2020	2021	2022	2023 YTD <sup>2</sup>	Apr. 2023	5 years Ø	p.a. 5 years
Fund (USD)	26.95	14.85	17.63	-10.16	3.13	5.42	57.29	9.48
Ref. Index <sup>3</sup>	23.24	13.52	19.80	-5.41	1.84	3.50	65.99	10.67

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

<sup>3</sup> Reference Index in currency of share class (without costs)

The end of April ushered in the beginnings of a rotation from defensive mega cap biopharma towards the smaller end of the market. Sustainable Health Transformation is maintaining a structural overweight to innovative SMID cap names, which we expect to materially outpace larger cap peers from a growth perspective.

### Monthly performance

In April the fund performed positively with 5.4%. Sector allocation and stock selection contributed to the strong performance in April. Underweights to life sciences tools and healthcare distributors contributed, while an overweight to biotech detracted.

### YTD performance

YTD as of the end of April, the fund has delivered a positive performance of 3.1%. The strong performance compared to the healthcare market was primarily driven by our structural underweight to large cap biopharma, which we expect to lag as the Fed reaches the end of its tightening cycle. We continue to maintain an overweight to the more innovative SMID cap names.

### Performance contributors

Contributors included Eli Lilly, Philips and Intuitive Surgical. Eli Lilly extended its outperformance on the back of continued optimism surrounding the long-term market potential for Mounjaro. Philips rebounded after reporting in-line earnings, while Intuitive Surgical was an earnings beat-and-raise story.

### Performance detractors

Detractors included Bio-Rad, Avantor and AbbVie. Bio-Rad and Avantor both traded lower after Danaher's earnings read-through reignited fears of inventory destocking in the bioprocessing space. AbbVie underperformed in April after earnings showed incremental pricing pressure on its immunology portfolio.

### For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Matthew Konosky

Scott Wilkin

Caroline Wallace

# UBS Equity Sust Health Transformation

## Market exposure (%)

	Fund	Deviation from index
United States	64.81	-6.4
United Kingdom	11.19	+6.8
Switzerland	9.31	+1.6
Japan	4.11	-0.1
Netherlands	3.90	+3.7
Denmark	3.05	-1.3
China	2.13	+2.1
Germany	1.18	-0.9
Canada	0.31	+0.3
Others	0.01	-5.7

## 10 largest equity positions (%)

	Fund
UnitedHealth Group Inc	9.24
Eli Lilly & Co	7.93
AstraZeneca PLC	6.67
Novartis AG	5.72
AbbVie Inc	5.66
Haleon PLC	4.44
Centene Corp	3.93
Koninklijke Philips NV	3.87
Intuitive Surgical Inc	3.74
Abbott Laboratories	3.59

## Thematic Exposure

	Fund
Health Tech	17.5
Oncology	16.4
Aging in comfort	15.7
Genetic Therapies	13.1
Obesity	9.2
Medical devices	8.2
EM Healthcare	1.1
Others	18.8

## Current investment strategy

In our view, we are poised for an era of greater dispersion in the healthcare sector more broadly. While the demand for healthcare will certainly not diminish, we believe that the underlying drivers – including ageing, obesity and mental health – will favour innovative SMID cap names, where we continue to maintain an overweight.

## Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary). © UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.